Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics.

Bourner J. et al, (2025), Emerging infectious diseases, 31, 9 - 16

Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use'.

Hassan MZ. et al, (2025), The Lancet regional health. Southeast Asia, 33

Clinical characterisation and outcomes of human clade IIb mpox virus disease - a European multicentre observational cohort study (MOSAIC).

Pesonel E. et al, (2025), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

The priority review voucher: a misconceived quid pro quo.

Olliaro P. and Torreele E., (2024), BMJ Glob Health, 9

Interpretations of Studies on SARS-CoV-2 Vaccination and Post-acute COVID-19 Sequelae.

Gonçalves BP. et al, (2024), Epidemiology (Cambridge, Mass.), 35, 368 - 371

Systematic Review of Scales for Measuring Infectious Disease–Related Stigma

Paterson A. et al, (2024), Emerging Infectious Diseases, 30

Implementation of Recommendations on the Use of Corticosteroids in Severe COVID-19.

Camirand-Lemyre F. et al, (2023), JAMA network open, 6

Variability in clinical assessment of clade IIb mpox lesions

Jones B. et al, (2023), International Journal of Infectious Diseases, 137, 60 - 62

Laboratory Diagnosis of Mpox, Central African Republic, 2016-2022.

Garba-Ouangole S. et al, (2023), Emerging infectious diseases, 29, 1846 - 1849

A Qualitative Assessment of a Training and Communication Intervention on Antibiotic Prescription Practices Among Health Workers and Outpatients at Public Health Facilities in Uganda.

Kaawa-Mafigiri D. et al, (2023), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 77, S191 - S198

Breakthrough treatments for Ebola virus disease, but no access-what went wrong, and how can we do better?

Torreele E. et al, (2023), The Lancet. Infectious diseases, 23, e253 - e258

[MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks].

Kali S. et al, (2023), Virologie (Montrouge, France), 27, 23 - 26

MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks.

Kali S. et al, (2023), Virologie (Montrouge, France), 27, 12 - 15

A legacy of progress in clinical pharmacology and social justice; remembering Peter Ian Folb.

Barnes KI. et al, (2023), Bulletin of the World Health Organization, 101, 3 - 3A

Plague

Rajerison M. et al, (2023), Manson's Tropical Diseases, Fourth Edition, 447 - 454

Tecovirimat for Monkeypox in Central African Republic under Expanded Access.

Mbrenga F. et al, (2022), The New England journal of medicine, 387, 2294 - 2295

Monkeypox: how will we know if the treatments work?

Rojek A. et al, (2022), The Lancet. Infectious diseases, 22, 1269 - 1270

Load More